MarketLens
Sign Up

Why Are Institutional Giants Like Manulife Betting Big on AstraZeneca

6 months ago
SHARE THIS ON:

Why Are Institutional Giants Like Manulife Betting Big on AstraZeneca

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Is AstraZeneca's Oncology Portfolio Positioned for Continued Growth?

AstraZeneca's oncology sales rose 15% in H1 2026, driven by newer drugs, label expansions, and a deep pipeline, supporting continued franchise growth.
Stock News•2 months ago

Is It Worth Investing in Astrazeneca (AZN) Based on Wall Street's Bullish Views?

AstraZeneca (AZN) is the subject of a media piece examining whether Wall Street's bullish analyst views justify investment, though no specific rating changes or price targets are cited. The article no...
Stock News•4 months ago

Astrazeneca Plc $AZN Shares Acquired by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale boosted its AstraZeneca holdings by 4,529% in Q1, acquiring 3.7M additional shares. The stake now represents ~1.2% of the fund's portfolio.

Breaking News

View All →

Top Headlines

View More →
Stock News•18 minutes ago

California AG Rob Bonta serves Nvidia with subpoena in wake of ex-CEO Jensen Huang's Chinese spy, affairs scandals

Stock News•48 minutes ago

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages NVIDIA Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NVDA

Stock News•50 minutes ago

Alibaba defrauded shareholders by concealing ties to suspected spy in Nvidia scandal, lawsuit says

Stock News•1 hour ago

GOOGL; GOOG DEADLINE FOR INVESTORS: Alphabet Inc. Shareholders Encouraged to Contact Kirby McInerney LLP By December 1, 2026

Stock News•1 hour ago

California AG issues subpoena to Nvidia in probe of China chips